- Home
- GCMG vs OCS Comparison
GCMG vs OCS Comparison
Compare GCMG & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCMG | OCS |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.6M | 732.4M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GCMG | OCS |
|---|---|---|
| Price | $12.75 | $10.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $14.33 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 388.1K | 144.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 1300.00 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $557,565,000.00 | N/A |
| Revenue This Year | $7.28 | $466.06 |
| Revenue Next Year | $11.70 | $479.73 |
| P/E Ratio | $75.88 | ★ N/A |
| Revenue Growth | ★ 8.47 | N/A |
| 52 Week Low | $9.30 | $10.52 |
| 52 Week High | $14.87 | $34.48 |
Technical Indicators
Market Signals| Indicator | GCMG | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 30.04 |
| Support Level | $11.25 | $10.63 |
| Resistance Level | $13.94 | $13.49 |
| Average True Range (ATR) | 0.31 | 0.45 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 4.84 | 13.43 |
Price Performance
Historical ComparisonAbout GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG, and absolute return strategies. The company invests maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.